Positive Report for Pro Medicus Limited (PMCUF) from Bell Potter
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2025
0mins
Source: Business Insider
Analyst Upgrade: John Hester from Bell Potter upgraded Pro Medicus Limited to a Buy with a price target of A$330.00, while Goldman Sachs maintained a Buy rating with a target of A$309.00, despite the current consensus being a Hold at A$163.74.
Financial Performance and Insider Sentiment: Pro Medicus reported strong quarterly earnings with revenue of $87.39 million and a net profit of $46.54 million, but insider sentiment is negative as there has been an increase in insiders selling shares.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
